Proteros and University of Cincinnati, Drug Discovery Center establish collaboration to offer high-throughput screening services
Proteros Biostructures GmbH announced that it has entered into an agreement with University of Cincinnati, Drug Discovery Center (UC DDC), under which Proteros will provide biotech and pharmaceutical companies with access to UC DDC’s ultra-high-throughput and high-content screening platform coupled with a 340,000-plus library of drug-like compounds. Proteros will be responsible for all the client interactions and project management providing a single point of contact.
Proteros now offers a comprehensive range of services for drug discovery from its own integrated lead discovery platform that includes a 30,000 member proprietary compound and fragment library, innovative kinetic and thermodynamic HTS assay technologies and structure guided medicinal chemistry to a traditional high-throughput screening approach. The structure guided approach is particularly suited to kinase targets, epigenetics targets and protein- protein interactions.
Cony D’Cruz Chief Business Officer and President Proteros US, Inc. stated, “We are very pleased to be able to offer this broad collection of discovery services to meet the diverse target and project needs of our clients. Proteros continues to enhance its service offering to enable our clients to improve the quality and productivity of their discovery efforts.”
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Beckman Coulter Announces the Creation of Beckman Coulter Genomics - New Company Offers Comprehensive Genomic Services
Bruker to acquire the NanoString business in an asset deal
Ultrasonic Scientific Expands its Operations with the Appointments of Italien and Japanese Distributors
DNTOX receives €1.4 million seed funding for non-animal testing of chemicals - The new capital will be used to set up the test laboratories in Düsseldorf, aim for GLP accreditation and launch the test battery on the market
Oxford Instruments announces major technology licensing deal with GE Healthcare - Result will be powerful new tool for in vitro molecular analysis
